SGN-CD33A: Overcoming Multi-Drug Resistance in AML Through Targeted Pyrrolobenzodiazepine Dimer Therapy
SGN-CD33A was found to be highly effective against a variety of AML cell lines and patient samples, including those with multidrug resistance (MDR). It showed superior activity compared to Gemtuzumab ozogamicin (GO), a currently used anti-CD33 monoclonal antibody. Resistance to SGN-CD33A was associated with low CD33 expression.
In vivo studies using AML mouse xenograft models demonstrated that SGN-CD33A could induce complete regressions and significantly delay tumor growth in drug-resistant AML, even at lower doses. GO showed minimal activity in comparison.
The results suggest that SGN-CD33A has potent antitumor activity against primary AML samples and could be effective in overcoming multidrug resistance. Clinical trials are planned to further assess its efficacy in AML treatment. Several authors are affiliated with Seattle Genetics, Inc., indicating a potential conflict of interest.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.
Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.
By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.
Click on the image below to go directly to the Translational Medicine search interface.
